Apogee Therapeutics, Inc. (APGE) Stock

Apogee Therapeutics, Inc. (APGE) is a Healthcare stock trading at $90.43 (as of 2026-06-18), with a market capitalization of $6.30B and a trailing P/E of -20.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Apogee Therapeutics, Inc. is a biotechnology company developing biologic therapies for atopic dermatitis and chronic obstructive pulmonary disease, along with related inflammatory and immunology indications. Its pipeline includes APG777 for atopic dermatitis and APG808 for COPD, both designed as subcutaneous, extended half-life monoclonal antibodies.

Valuation — source: SEC EDGAR (first-party)
Price	$90.43
Market Cap	$6.30B
P/E Ratio	-20.4
EV / EBITDA	-20.3
Price / Sales	213.85
DCF Value (model)	$-55.97
DCF Upside vs Price	-161.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$30.03M
Net Margin	-852.0%
Current Ratio	32.59
Revenue Growth (YoY)	-13.6%
EPS Growth (YoY)	27.9%
FCF Growth (YoY)	35.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	110.72 (safe)

Valuation vs Sector & Industry
Stock P/E	-20.4
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-197.3%
vs Industry	-218.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	T. Rowe Price Investment Management, Inc. ($867.03M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Michael Thomas Henderson
Employees	196
Country	US
IPO Date	2023-07-14

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.